ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MLSS / earnings
LFWD (32) HSCS (38) MYO (31) COCH (36) ⌘ Pro Terminal →

Milestone Scientific Inc. (MLSS) Next Earnings Date & Expected ±12.5% Move

$0.32 +5.88% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.32

Milestone Scientific Inc. (MLSS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $27.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MLSS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MLSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Milestone Scientific Inc. (NYSE: MLSS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.32 (+5.88% 1D, market cap $27.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, MLSS ranks #467 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MLSS compare to LFWD and HSCS in the Health Care sector?
▼

Within the Health Care sector (Industrial Specialties), MLSS carries a Roarable D- (40/100 RQD), trailing P/E of 5.0x, gross margin of 71.4%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $16.9M) and HSCS (HeartSciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while MLSS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MLSS?
▼

Per MLSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000855683), Milestone Scientific Inc. generated $9.0M in revenue (+4.0% YoY), $5.7M in net income, and -$2.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.32 (+0.87%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (4)Whales (12)SEC (13)Macro (4)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$1 Bull$0 Base$0 Bear
📬 FREE MLSS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MLSS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY MLSS SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (35.4) create a -16 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$0.34+0% Next Q
Q2 (-2Q)
45
Grade D$0.34-11.8% Next Q
Q3 (-1Q)
43
Grade D$0.30+6.7% Next Q
Current
40
Grade D-$0.32-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MLSS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MLSS currently carries a cautious 40/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.39) and Max Pain ($0.34) forces dealer call-delta covering toward $0.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MLSS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MLSS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.04 Expected Swing
$1.00 (-12.5%)Spot $0.32$0.36 (+12.5%)
MODEL EARNINGS SETUP GAUGE

MLSS Quantitative Pre-Earnings Setup: 40/100

Trailing EPS: $0.20 • YoY Revenue Growth: 12.4%

Model Bullish Setup (40/100)Model Risk Weight (60/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$9.0M$5.7M-$2.9M71.4%
FY 20242024-12-31$8.6M$4.7M-$2.9M74.6%
FY 20232023-12-31$19.9M$6.9M-$5.3M71.4%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MLSS)

  • ✓Walkthrough of MLSS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MLSS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.57%📐 HORIZONTAL RANGE
2026-11-03O $0.31H $0.32L $0.30C $0.32VOL 42.0K
RES: $0.67SUP: $0.28SMA50: $0.39SMA200: $0.35
$0.60$0.52$0.43$0.35$0.26RES $0.67SUP $0.28$0.322026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MLSS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MLSS Butterfly Map → + Track MLSS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-14.0%/yr Implied 5Y Growth

vs. +4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MLSS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MLSS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MLSS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MLSS)

Health Care Rank #467 of 1015 ⚔️ LFWD vs MLSS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MLSS vs. LFWD, HSCS, MYO, COCH)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Milestone Scientific Inc. (MLSS) ranks #467 by composite RQD confidence (40/100, grade D-) and #806 by equity capitalization ($27.6M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while MLSS leads on capital efficiency and profitability with -35.0% ROIC and 71.4% gross margin. MLSS currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MLSS ACTIVE
Milestone Scientific Inc.
D- 40/100 5.0x 71.4% -35.0% +5.88% $27.6M Benchmark Subject
LFWD
Lifeward Ltd.
E 32/100 — 96.0% -35.0% +1.82% $16.9M /lfwd-vs-mlss →
HSCS
HeartSciences Inc.
D- 38/100 — 59.1% -35.0% -9.67% $16.0M /hscs-vs-mlss →
MYO
Myomo Inc.
E 31/100 — 65.7% -35.0% -3.23% $49.1M /myo-vs-mlss →
COCH
Envoy Medical Inc. (Class A)
D- 36/100 — -30.0% -35.0% +0.30% $51.3M /coch-vs-mlss →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000855683 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Scientific Inc. (MLSS) reported GAAP revenue of $9.0M (+4.0% vs. FY2024 revenue of $8.6M , and -54.9% cumulative change since FY2023) , GAAP net income of $5.7M, operating cash flow of -$2.9M, and free cash flow of -$2.9M (-0.1% YoY). On the balance sheet, MLSS closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $9.0M $5.7M -$2.9M -$2.9M $7.8M —
FY2024 (FY) 2024-12-31 $8.6M $4.7M -$2.9M -$2.9M $9.8M —
FY2023 (FY) 2023-12-31 $19.9M $6.9M -$5.3M -$5.3M — —

3. MLSS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MLSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Milestone Scientific Inc. (NYSE: MLSS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.32 (+5.88% 1D, market cap $27.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, MLSS ranks #467 in composite RQD confidence.

How does MLSS compare to LFWD and HSCS in the Health Care sector?

Within the Health Care sector (Industrial Specialties), MLSS carries a Roarable D- (40/100 RQD), trailing P/E of 5.0x, gross margin of 71.4%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $16.9M) and HSCS (HeartSciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while MLSS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MLSS?

Per MLSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000855683), Milestone Scientific Inc. generated $9.0M in revenue (+4.0% YoY), $5.7M in net income, and -$2.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MLSS trading relative to its 50-day, 200-day, and 52-week technical levels?

MLSS last traded at $0.32 (+5.88% on volume of 126,408 shares), positioning the stock -17.95% below its 50-day simple moving average ($0.39) and -8.57% below its 200-day simple moving average ($0.35). Across its 52-week range of $0.22 to $0.58, MLSS sits at the 27.8% percentile with a 14-day RSI of 35.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.36).

Direct Sub-Reports: MLSS RQD Cockpit MLSS 12M Forecast MLSS Earnings & Move MLSS Dividends & DRIP MLSS Insiders & 13F MLSS Whale Options MLSS Profit Sankey MLSS News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MLSS — Milestone Scientific Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Milestone Scientific Inc. (MLSS) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.32 (+5.88% 1D, market capitalization $27.6M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 71.4%, operating margin of -60.0%, and free cash flow yield of -10.27%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Milestone Scientific Inc. Is a NYSE-listed issuer classified in the Health Care sector and Industrial Specialties industry,. The company reported revenue of $9.0M for FY 2025 and $8.6M for FY 2024. Per the market data, gross margin is 71.4%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Milestone Scientific Inc. (MLSS) reported $9.0M in annual revenue (up from $8.6M in FY2024, +4.0% YoY) and $5.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($19.9M revenue, $6.9M net income) through FY2025, MLSS scaled operating cash flow to -$2.9M and free cash flow to -$2.9M, backed by $7.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.27% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $0.22 – $0.58 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 5.0x trailing P/E against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream supplier dependencies, downstream customer concentration, or 2nd-order bottlenecks.

  • Key Question #1: Can MLSS sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $9.0M and free cash flow of -$2.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MLSS's 4.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MLSS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Milestone Scientific Inc. (MLSS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MLSS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MLSS Bull vs. Bear Conversation Board — What's Your Call at $0.32?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MLSS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MLSS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $0.38 (+26.7%)
📌 Pinned Debate

Low headline valuation (P/E TTM of 5, Forward P/E of 4.7) combined with a GREEN-flagged CompuFlo® commercial growth catalyst across 30

Picked up a starter position in MLSS in my $100K Virtual Cash book at $0.30. Low headline valuation (P/E TTM of 5, Forward P/E of 4.7) combined with a GREEN-flagged CompuFlo® commercial growth catalyst across 30 million+ annual global epidural procedures.. Trading inside a $0.22–$0.58 52-week range with -10.27% FCF yield gives solid downside support if Industrial Specialties multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 12/20 institutional whale-flow stock at $0.30 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.24 (-20.0%)
Spot @ $0.30

Negative ROIC of -35%, negative free cash flow in each reported year, and cash falling from $3.3M to $1.1M, with a -60% operating margi

Negative ROIC of -35%, negative free cash flow in each reported year, and cash falling from $3.3M to $1.1M, with a -60% operating margin that the data does not reconcile against positive net income.. Look at the math on MLSS: paying 5.0x trailing P/E for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $0.26 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%